Johnson and Johnson’s COVID-19 immunization produces solid invulnerable reaction in early preliminary Kumar Jeetendra | September 26, 2020 Pharmaceutical giant Johnson & Johnson’s experimental COVID-19 vaccine has produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, in accordance with the data published on September 25. “The data demonstrate that a single dose of COVID-19 vaccine, Ad26.COV2.S, induced a powerful neutralising antibody response in nearly all participants aged …
Indo-Israel fast COVID-19 testing examination to fructify in ‘matter of days’: Israeli agent Kumar Jeetendra | October 9, 2020 A game-changer rapid COVID-19 testing technologies being jointly developed by India and Israel should be prepared for rollout in”a matter of days” and it’ll have the ability to give test results in less than a minute by simply requiring an individual to blow into a tube, the Israeli envoy to India has stated. Ambassador Ron …
Bharat Biotech requested to submit total phase 2 information of its COVID-19 antibody before ph 3 preliminary Kumar Jeetendra | October 10, 2020 According to officials, the Hyderabad-based vaccine manufacturer applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to run phase-3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate. The firm in its program said that the study would cover 28,500 subjects aged 18 years and above and would …
Pfizer, BioNTech start consolidated preliminaries of COVID-19 immunization candidate in Japan Kumar Jeetendra | October 20, 2020 Pfizer Inc and BioNTech SE announced on Tuesday the start in Japan of combined Phase I and Phase II clinical trials of the mRNA vaccine candidate against the coronavirus. Earlier, they had agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021. Pfizer, which is developing …
Russia signs more deal with India to make 300 million Sputnik V immunizations Kumar Jeetendra | December 18, 2020 India will produce about 300 million doses of Russia’s Sputnik V coronavirus vaccines next year, a Russian official was quoted as saying, almost three times the previously known number as deals are signed with more manufacturers. Russia is already testing the first samples of Sputnik V that were created in India, its embassy in New …
New strain of coronavirus driving second wave of cases in South Africa Kumar Jeetendra | December 19, 2020 South African Health Minister Zweli Mkhize has said that a new strain of the novel coronavirus was identified which was spreading faster, driving the second wave of the pandemic the nation was going through. He said people should worry about this new variant of this virus, but there was no reason to panic. As South …
Oxford COVID-19 vaccine may also come to be the primary to get Indian regulator’s nod for emergency use Kumar Jeetendra | December 26, 2020 With preparations underway for a possible vaccine-rollout by January, the Indian drug regulator is considering the united kingdom, which sources consider may give its nod to the Oxford COVID-19 vaccine following week, before deciding on giving emergency use authorisation to the Serum Institute that’s manufacturing the shots . When the UK drug regulator gives its …
Russia prepared to trial combined AstraZeneca, Sputnik V antibody in Ukraine Kumar Jeetendra | January 3, 2021 Russia is ready to run clinical trials in Ukraine of a COVID-19 vaccine combining its Sputnik V with a vaccine developed by AstraZeneca together with Oxford University, the head of Russian Direct Investment Fund (RDIF) said on Saturday. Russia’s autonomous RDIF, which is marketing the Sputnik V vaccine overseas, announced in December trials to test …
India needs Pfizer to do nearby examination for approval: Official Kumar Jeetendra | January 13, 2021 Any vaccine manufacturer, such as Pfizer Inc, which has sought emergency-use authorisation for its COVID-19 shot in India, must run a neighborhood”bridging” safety and immunogenicity study to be considered for the country’s immunisation programme, a senior government official told Reuters. Serum Institute of India, the local maker of the vaccine developed by AstraZeneca Plc and …
British intelligence trusts COVID-19 lab spill hypothesis ‘feasible’: Report Kumar Jeetendra | May 31, 2021 More than 170 million confirmed cases have since been confirmed worldwide and at least 3.5 million deaths reported. British intelligence agencies now believe it is “feasible” that the COVID-19 pandemic began with a coronavirus leak from a Chinese bio laboratory, a media report said, prompting Vaccines Minister Nadhim Zahawi to demand that the WHO must …
Which COVID vaccine is ideal? Here’s the reason that is truly difficult to reply Kumar Jeetendra | June 17, 2021 With the rollout of COVID-19 vaccines accelerating, people are increasingly asking which vaccine is best? Even if we tried to answer this question, defining which vaccine is “best” is not simple. Does that mean the vaccine better at protecting you from serious disease? The one that protects you from whichever variant is circulating near you? …
AstraZeneca vaccine’s investigator backs India’s 12–16-week Covishield dose gap Kumar Jeetendra | June 19, 2021 Backing the 12-16 weeks gap between the two doses of Covishield in India, the chief investigator of the AstraZeneca vaccine clinical trials on June 18 said that the level of protection provided by one dose of the preventive significantly increases in the second and third months after the jab. In an interview with The Wire, …
